• Hamlet Biopharma AB began the clinical phase of its Phase III trial in non-muscle invasive bladder cancer, with patients now enrolling.
• Results have not been presented; the update covers trial start-up and initial patient treatment under the protocol.
• The milestone advances the company’s lead program, supported by Phase III-quality Alpha1H manufacturing and delivery to the Prague trial site.
• Hamlet Biopharma is also preparing a separate study in therapy-resistant cancer in situ at the University of Iowa urology department.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260917:BIT:1643:0) on September 17, 2026, and is solely responsible for the information contained therein.